

Poly(ADP) ribose polymerase-1 ablation alters eicosanoid and docosanoid signaling and metabolism in a murine model of contact hypersensitivity

BORBÁLA KISS^{1*}, MAGDOLNA SZÁNTÓ^{2,3*}, MÓNIKA SZKLENÁR⁴, ATTILA BRUNYÁNSZKI²,
TAMÁS MAROSVÖLGYI⁵, ESZTER SÁROSI⁵, ÉVA REMENYIK¹,
PÁL GERGELY², LÁSZLÓ VIRÁG^{2,3}, TAMÁS DECSI⁵, RALPH RÜHL⁶ and PETER BAI^{2,7,8}

Departments of ¹Dermatology and ²Medical Chemistry, University of Debrecen, H-4032 Debrecen;

³MTA-DE Cell Biology and Signaling Research Group of the Hungarian Academy of Sciences, H-4032 Debrecen;

⁴Paprika Bioanalytics Bt., H-4032 Debrecen; ⁵Department of Pediatrics, University of Pécs, H-7623 Pécs;

⁶Department of Biochemistry and Molecular Biology and ⁷Research Center for Molecular Medicine, University of Debrecen, H-4032 Debrecen; ⁸MTA-DE Lendület Laboratory of the Cellular Metabolism Research Group, H-4032 Debrecen, Hungary

Received January 22, 2014; Accepted September 24, 2014

DOI: 10.3892/mmr.2014.3044

Abstract. Poly(ADP-ribose) polymerase (PARP)-1 is a pro-inflammatory protein. The inhibition of PARP-1 reduces the activity of numerous pro-inflammatory transcription factors, which results in the reduced production of pro-inflammatory cytokines, chemokines, matrix metalloproteinases and inducible nitric oxide synthase, culminating in reduced inflammation of the skin and other organs. The aim of the present study was to investigate the effects of the deletion of PARP-1 expression on polyunsaturated fatty acids (PUFA), and PUFA metabolite composition, in mice under control conditions or

undergoing an oxazolone (OXA)-induced contact hypersensitivity reaction (CHS). CHS was elicited using OXA in both the PARP-1^{+/+} and PARP-1^{-/-} mice, and the concentration of PUFAs and PUFA metabolites in the diseased skin were assessed using lipidomics experiments. The levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were shown to be increased in the PARP-1^{-/-} mice, as compared with the control, unsensitized PARP-1^{+/+} mice. In addition, higher expression levels of fatty acid binding protein 7 (FABP7) were detected in the PARP-1^{-/-} mice. FABP7 is considered to be a specific carrier of DHA and EPA. Furthermore, the levels of the metabolites of DHA and EPA (considered mainly as anti-inflammatory or pro-resolving factors) were higher, as compared with the metabolites of arachidonic acid (considered mainly pro-inflammatory), both in the unsensitized control and OXA-sensitized PARP-1^{-/-} mice. The results of the present study suggest that the genetic deletion of PARP-1 may affect the PUFA-homeostasis of the skin, resulting in an anti-inflammatory milieu, including increased DHA and EPA levels, and DHA and EPA metabolite levels. This may be an important component of the anti-inflammatory action of PARP-1 inhibition.

Correspondence to: Dr Peter Bai, Department of Medical Chemistry, University of Debrecen, Nagyerdei krt 98. Pf. 7. H-4032 Debrecen, Hungary
E-mail: baip@med.unideb.hu

Dr Ralph Rühl, Department of Biochemistry and Molecular Biology, University of Debrecen, Nagyerdei krt 98, H-4032 Debrecen, Hungary
E-mail: ralphruehl@web.de

*Contributed equally

Abbreviations: AA, arachidonic acid; CHS, contact hypersensitivity; COX, cyclooxygenase; DAPI, 4,6-diamidino-2-phenylindole; DHA, docosahexaenoic acid; DHGLA, dihomog- γ -linoleic acid; EPA, eicosapentaenoic acid; FABP, fatty acid binding proteins; MET, metabolite; OXA, oxazolone; PARP, poly(ADP-ribose) polymerase; PUFAs, polyunsaturated fatty acids; Pg, prostaglandin

Key words: PARP-1, PUFA, contact hypersensitivity, oxazolone, DHA, EPA, FABP7, lipidomics, inflammation, cyclooxygenase-2

Introduction

Poly(ADP-ribose) polymerases (PARPs) comprise a superfamily containing 17 members in humans (1). Numerous PARP-1, -2, -14 and tankyrases have previously been shown to mediate inflammatory reactions (2-6), and PARP-1 has been associated with inflammatory or oxidative stress-related skin pathologies (7-9). PARP-1 is an important pro-inflammatory mediator with important roles in the maturation of immune cells (10-12), activation of pattern recognition receptors (13-19), activation of pro-inflammatory transcription factors (6), and reactive species (20).

The contact hypersensitivity (CHS) reaction is a T-cell mediated, delayed type hypersensitivity reaction that is elicited by low molecular weight molecules, such as oxazolone (OXA) (21,22). Upon sensitization, infiltrating cells and keratinocytes produce free radicals, pro-inflammatory cytokines, adhesion molecules and matrix metalloproteinases in a PARP-1 and nuclear factor- κ B-dependent manner, resulting in the induction of inflammation (6,7,20,23-25). PARP-1 expression inhibition, or knock-out, has been shown to reduce the severity of experimental CHS (7,26). The present study aimed to characterize whether alterations of eicosanoid and docosanoid metabolism and signaling may contribute to the anti-inflammatory effects of PARP-1 expression ablation.

Materials and methods

Materials. OXA and the other chemicals used in the present study were obtained from Sigma-Aldrich (St. Louis, MO, USA), unless stated otherwise.

Animal experiments. All of the experiments performed on mice were approved by the Local Ethical Committee (9/2008/DE MÁB) and were performed according to EU and national guidelines. PARP-1^{+/+} and PARP-1^{-/-} mice, derived from heterozygote-to-heterozygote breeding, were kept in the animal facility of the Life Science Building, University of Debrecen (Debrecen, Hungary) (27). A CHS model was constructed as described by previous methods (7). Briefly, the mice were randomized into four groups: PARP-1^{+/+} vehicle sensitized (control), PARP-1^{-/-} vehicle sensitized (control), PARP-1^{+/+} OXA sensitized (CHS) and PARP-1^{-/-} OXA sensitized (CHS) groups ($n=5/5/6/5$). Sensitization was carried out on the shaved abdominal wall skin of the mice, with an administration of 100 μ l 2% OXA solubilised in acetone : olive oil (4:1; CHS groups), or 100 μ l vehicle of acetone:olive oil (4:1; control groups). Seven days after sensitization, all of the mice were challenged with 100 μ l 0.5% OXA, which was applied to the epidermis of the shaved back. After 24 h, the mice were sacrificed and the skin was harvested.

Histology and microscopy. Hematoxylin-eosin staining and immunohistochemistry was performed on paraffin-fixed 7 μ m tissue sections, as described previously (7).

High performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS-MS) analysis. The procedure for the HPLC-ESI-MS-MS analysis The analysis of free fatty acids, eicosanoids and docosanoids in the skin was performed, according to previously described methods (28), with minor modifications.

Sample preparation. The whole analytical sample preparation procedure used was based on an established method used for retinoid quantification (29). Briefly, 50 mg skin biopsy, was treated with 150 μ l acetonitrile and the skin samples were cut into small pieces with scissors, on ice. If less than 50 mg of skin biopsy was present, water was added to yield 50 mg of sample weight. The mixtures were agitated for 3 min, and the precipitated protein was centrifuged at 16060 g (13,000 rpm), 4°C for 6 min. A total of 130 μ l resulting supernatant was mixed with 10 μ l isotope supernatant mix and evaporated in

Eppendorf reaction vials (Eppendorf, Hamburg, Germany) using an Eppendorf concentrator at 30°C for ~60 min, until the sample volume was ~10 μ l. The Eppendorf concentrator was vented with argon, in order to prevent degradation of eicosanoids and docosanoids. The dried extract was resuspended in ~25 μ l HPLC solvent A [64.3% water (Chromasolv Plus; Sigma-Aldrich, Budapest, Hungary), 35.5% acetonitrile (Merck KGaA, Darmstadt, Germany) and 0.2% formic acid (Sigma-Aldrich, Hungary)] to yield 35 μ l. The sample was then vortexed (15 sec), agitated (3 min) and transferred into micro injection inserts vials (Waters, Budapest, Hungary). The glass vials containing 35 μ l extract were transferred into brown screw top vials with PTFE/silicone septa (Waters), and placed into the pre-cooled (15°C) autosampler of the Waters 2695XE separation module.

Chromatographic system. The HPLC system consisted of a Waters 2695XE separation module (Waters) including a gradient pump, autosampler, degasser and a heated column compartment. A MS-MS detector, with an ESI ionizing option, (Micromass Quattro Ultima PT; Waters, Elstree, UK; a gift from Biosystems Int., France) was used as the detector. The system was controlled using MassLynx software (Waters).

HPLC conditions. The eluents were degassed in the Waters 2695XE separation module prior to mixing, and passed through an in-line filter (1-2 μ m; Knauer, Berlin, Germany) before reaching the analytical column (LiChroCART, 125x2 mm; Superspher 100, RP-18, endcapped; Merck KGaA), which was embedded in the column compartment. A multilinear gradient was formed from solvent A (as mentioned previously) and solvent B (methanol; Merck KGaA). The gradient consisted of the following steps: 0.0 min 20% B, 3.0 min 20% B, 5.0 min 60% B, 15.0 min 100% B, 15.9 min 100% B and 16.0 min 5% B. The flow rate was adjusted to 0.4 ml/min and the column was heated to 40°C. From the same biological extract, 10 μ l was used for each HPLC analysis. This step was performed twice, using the same HPLC conditions, and two different MS-MS analysis options were conducted for better resolution and quantification of the various analytes.

MS options. The Micromass Quattro Ultima PT was controlled using MassLynx software. Argon was used with an inlet pressure of 0.8 bar. ESI (electro spray ionization source; Waters) was vented by nitrogen, which was continuously produced by a nitrogen generator (Peak Scientific NM30 Nitrogen generator; Peak Scientific, Billerica, MA, USA) including a compressor (Waters), the inlet flow was set at 3.6×10^{-3} mbar.

Multiple reaction monitoring settings. ESI, with a negative ESI-setting, was performed with the HPLC eluent, following the ion source temperature of 85°C. The desolvation gas flow was 780 l/h, the desolvation temperature was 400°C, the cone gas flow was 10 l/h, the capillary current was 3 μ A, and the cone voltage was 50 V. The aperture voltage was set at 0 V and the range-finder lens voltage was set at 35 V (for one) and 0.2 V (for two). The analyzer settings were LM1 resolution, 14.5; HM1 resolution, 14.5; ion energy, 10.7; entrance, -1; collision, 0 (collision parameters were set for each substance at the MS-method parameters); exit, 2; LM2 resolution, 14.5; HM2 resolution, 14.5; ion energy, 25.0 and multiplier energy, 650 V.

Table I. Oligonucleotides used in quantitative polymerase chain reactions.

| Gene | Sequence |
|--------------------|--|
| Mouse 36B4 | 5'-AGA TTC GGG ATA TGC TGT TGG-3' 5'-AAA GCC TGG AAG AAG GAG GTC-3' |
| Mouse GAPDH | 5'-CAA GGT CAT CCA TGA CAA CTT TG-3' 5'-GGC CAT CCA CAG TCT TCT GG-3' |
| Mouse cyclophyllin | 5'-TGG AGA GCA CCA AGA CAG ACA-3' 5'-TGC CGG AGT CGA CAA TGA T-3' |
| Mouse FABP7 | 5'-GAG TAC ATG AAA GCT CTG GGC-3' 5'-AAC CGA ACC ACA GAC TTA CAGT T-3' |
| Mouse COX2 | 5'-GTG AAG GGA AAT AAG GAG CTT CC-3' 5'-GTG ATT TAA GTC CAC TCC ATG GC-3' |
| Human 36B4 | 5'-CCA TTG AAA TCC TGA GTG ATG TG-3' 5'-GTC GAA CAC CTG CTG GAT GAC-3' |
| Human actin | 5'-GAC CCA GAT CAT GTT TGA GAC C-3' 5'-CAT CAC GAT GCC AGT GGT AC-3' |
| Human cyclophyllin | 5'-GTC TCC TTT GAG CTG TTT GCA GAC-3' 5'-CTT GCC ACC AGT GCC ATT ATG-3' |
| Human PARP-1 | 5'-CAC TGG TAC CAC TTC TCC TGC TTC-3' 5'-CTT TGC CTG TCA CTC CTC CAG-3' |

Multiple reaction monitoring settings for polyunsaturated fatty acids (PUFA), eicosanoids/docosanoids semi-quantification.

The following methods were used, as described in a previous study (27): Method A from 0.0-9.0 min for PGF₂ 349.0 → 192.7, collision energy 22 eV; PD1 and PD1 isomers, like PDX, 359.0 → 153.3, collision energy 17 eV; TXB₂ 369.0 → 195.0, collision energy 13 eV; PGE₃ 349.0 → 233.0, collision energy 17 eV; LXA₄ / LXB₄ 351.0 → 115.0, collision energy 12 eV; 8iPGF₃ 351.0 → 193.0, collision energy 22 eV; 20-COOH-LTB₄ 365.0 → 195.0, collision energy 13 eV; RvD1, RvD2 375.0 → 141.3, collision energy 13 eV; RvE1 375.1 → 141.3, collision energy 13 eV. From 9.0-12.5 min for 13-HODE 294.7 → 170.7, collision energy 16 eV; 9-HODE 294.7 → 194.7, collision energy 16 eV; 5-HEPE 317.0 → 115.0, collision energy 17 eV; 12-HEPE 317.0 → 179.0, collision energy 17 eV; 15-HEPE 317.0 → 219.0, collision energy 17 eV, LTC₄ 623.9 → 272.0, collision energy 14 eV. From 12.5-16.0 min for LA 279.3 → 279.0, collision energy 10 eV; 8-HEPE 317.0 → 255.0, collision energy 17 eV; 18-HEPE 317.0 → 259.0, collision energy 17 eV; 5-oxoETE, 12-oxoETE and 15-oxoETE 317.0 → 273.0, collision energy 17 eV; 20-HETE 319.0 → 245.0, collision energy 10 eV; LTC₄ 623.9 → 272.0, collision energy 14 eV; LTE₄ 438.0 → 333.0, collision energy 13 eV. From 12.5-16.0 min for LA 279.3 → 59.2, collision energy 25 eV; EPA 301.0 → 203.2, collision energy 12 eV; AA 303.0 → 259.3, collision energy 14 eV; DHA 327.1 → 29.3, collision energy 14 eV.

Method B (27) from 0.0-9.8 min for PGE₂, d15d12PGD₂, PGD₂, d15d12PGJ₂ and PGJ₂ 315.0 → 271.3, collision energy 13 eV; LTB₅ 333.0 → 195.0, collision energy 13 eV; LTB₄ 335.0 → 195.0, collision energy 13 eV; RvE₁ 349.1 → 195.3, collision energy 13 eV; HXA₃, HXB₃ and 20-COOH-AA 335.0 → 273.3, collision energy 13 eV; LXA₅ 349.0 → 115.0, collision energy 12 eV; 20-OH-LTB₄ 351.0 → 195.0, collision energy 13 eV;

MaR 359.0 → 250.0, collision energy 13 eV. From 9.8-12.5 min for 5-HETE 318.7 → 115.0, collision energy 14 eV; 8-HETE 319.0 → 155.0, collision energy 14 eV; 11-HETE 319.0 → 167.0, collision energy 14 eV; 12-HETE 319.0 → 179.0, collision energy 14 eV; 15-HETE 319.0 → 218.9, collision energy 11 eV; 4-HDHA 343.0 → 101.0, collision energy 10 eV; 10-HDHA 343.0 → 181.0, collision energy 10 eV; 14-HDHA 343.0 → 205.0, collision energy 10 eV; 17-HDHA 343.0 → 245.0, collision energy 14 eV; 20-HDHA 343.0 → 285.0, collision energy 10 eV; 13-oxoODE 293.0 → 249.0, collision energy 17 eV. And from 12.5-16.0 min for LA 279.3 → 59.2, collision energy 25 eV; EPA 301.0 → 203.2, collision energy 12 eV; AA 303.0 → 259.3, collision energy 11 eV; and DHA 327.1 → 229.3, collision energy 14 eV.

Standard solutions. Stock solutions of the PUFAs, eicosanoids and docosanoids were prepared by dissolving the solutions in methanol to yield a final concentration of 10 µg/ml. The solutions were obtained from Cayman-Chemicals (Tallinn, Estonia), BioMol International (Kastel-Med KFT, Budapest, Hungary), Sigma-Aldrich (Hungary), Larodan Lipids (Malmö, Sweden) and Dr. Charles Serhan (Harvard, MA, USA). All stock solutions were stored in the dark, at -80°C until further use. The reference PUFAs, eicosanoids and docosanoids (BioMol International/ Enzo Life Sciences, Farmingdale, NY, USA) were used for assay validation.

Quantification. Individual eicosanoids and docosanoids were quantified based on the determination of the area under the curve (AUC), which was compared with the AUC of the standard compounds. To ensure optimal extraction, isotope-labelled standard compounds were used. This analytical procedure was previously established for liquids and tissue analysis (28).




Figure 1. Deletion of poly(ADP-ribose) polymerase-1 (PARP-1) suppresses neutrophil migration. Formalin-fixed, paraffin-embedded tissue sections were stained with (A) hematoxylin and eosin and (B) DAPI counterstain (blue) and an anti-neutrophil elastase antibody (green) to detect neutrophil elastase. The arrows indicate the neutrophil elastase-positive cells. The neutrophil elastase staining was observed to be cytoplasmic. Scale bars: A, 30 μ m; B, 10 μ m.



Figure 2. Eicosanoid and docosanoid signaling alterations in the skin of poly(ADP-ribose) polymerase-1 (PARP-1)^{-/-} mice, due to enhanced fatty acid binding protein (FABP)7 expression. The FABP7 mRNA expression levels, and eicosanoid and docosanoid concentrations, were determined in the skin of control (PARP-1^{+/+} NS), OXA-sensitized PARP-1^{+/+} (PARP-1^{+/+} SENS) and respective PARP-1^{-/-} mice (n=5/5/6/5). AA, arachidonic acid; DHGLA, dihomo-gamma-linoleic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; MET, metabolites; COX, cyclooxygenase; COX2, cyclooxygenase 2; Pg, prostaglandin.




Figure 3. Reduction in the expression levels of poly(ADP-ribose) polymerase-1 (PARP-1) in response to specific small hairpin (sh)RNA treatment of HEK293T human embryonic kidney cells. PARP-shRNA also induced the activity of the fatty acid binding protein (FABP)7 promoter. (A) PARP-1 expression levels were reduced in HEK293T cells using a construct coding an shRNA against PARP-1 (shPARP-1), as determined by quantitative polymerase chain reaction (n=3/3). (B) Promoter activity of FABP7 was determined in luciferase reporter assays in control (scPARP-1 HEK293T) and shPARP-1 HEK293T cells (n=3/3). *P<0.05, PARP-1^{+/+} mice, compared with PARP-1^{-/-} mice; ***P<0.001, scPARP-1, compared with shPARP-1 HEK293T cells.

mRNA preparation, reverse transcription and quantitative polymerase chain reaction (qPCR). Total RNA extraction, reverse transcription, and a subsequent qPCR, were performed as described previously (7). The primers used are listed in Table I.

Establishment of a PARP-1 knockdown HEK293T cell line and luciferase reporter assays. HEK293T human embryonic kidney cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium, supplemented with 4.5 g/l glucose, 10% fetal calf serum, 2.5 µg/ml puromycin. These cells stable expressing a small hairpin (sh) RNA specifically targeting PARP-1 (pLKO.1-PARP1). pLKO.1 was used in the control cells (Sigma-Aldrich, USA). PARP-1 expression was subsequently suppressed, as confirmed by qPCR.

pLightSwitch_PromFABP7 (Switchgear Genomics, Carlsbad, CA, USA) and pCMV-βgal were transfected into

the above cell line using jetPEI (PolyPlus Transfections SA, Illkirch, France). Following a 24 h incubation, the luciferase and β-galactosidase activities were determined. Luciferase activity was normalized to β-galactosidase activity.

Statistical analysis. The results of the cell assays are expressed as the means ± standard deviation, and statistical significance between the groups was determined by Student's t-test. The results of the *in vivo* studies are expressed as the means, and statistical significance was determined using the Kruskal-Wallis and Mann-Whitney tests. A P<0.05 was considered to indicate a statistically significant difference.

Results

Neutrophil infiltration and edema at the site of the CHS reaction was observed in the histological examinations; however,

the levels of these were reduced in the PARP-1^{-/-} mice (Fig. 1A and B). This finding indicates that PARP-1 may contribute to inflammation in CHS, therefore PARP-1^{-/-} mice may be protected against CHS. These results are concordant with our previous observations (7,26,30).

The qPCR detected higher mRNA expression levels of fatty acid binding protein (FABP)7 in the PARP-1^{-/-} mice (Fig. 2). The depletion of PARP-1 expression (Fig. 3A) induced the activity of the FABP7 promoter (Fig. 3B), suggesting that PARP-1 may have direct effects on the FABP7 promoter.

Using a lipidomic approach, the composition of eicosanoids and docosanoids in the skin was determined. There was an increase in four of the major PUFAs, which are precursors of eicosanoids and docosanoids: Arachidonic acid (AA; 20:4 n-6), dihomogamma-linoleic acid (DHGLA; 20:3 n-6), docosahexaenoic acid (DHA; 22:5 n-3) and eicosapentaenoic acid (EPA; 20:5 n-3). These free fatty acids had increased levels in the skin of the control and OXA-challenged PARP-1^{-/-} mice, as compared with their respective PARP-1^{+/+} cohorts (Fig. 2).

The levels of AA-metabolites (AA MET), as compared with the mother compound AA (AA MET/AA), as well as EPA MET/EPA and DHA MET/DHA, had lower ratios in the non-sensitized animals, and the n3-PUFAs ratios were increased in the sensitized animals (Fig. 2). The sum of the cyclooxygenase (COX) metabolites (COX SUM), and the levels of COX metabolites prostaglandin E2 (PGE2) and PGE2, as well as the PGE2/AA and PGE2/DHA ratios, were all decreased showing reduced synthesis of pro-inflammatory lipid mediators. The levels of anti-inflammatory or pro-resolving n3-PUFA metabolites were mainly increased, resulting from EPA and DHA-metabolism (31) in the PARP-1^{-/-} animals (Fig. 2). These data are concordant with the decreased expression levels of COX-2 in the PARP-1^{-/-} mice (Fig. 2).

Discussion

In the present study, it was determined that ablation of PARP-1 expression had characteristic effects on skin eicosanoid and docosanoid signaling, and metabolism. The two n-3 PUFAs (DHA and EPA), DHA- and EPA-metabolites, and the ratios of DHA- and EPA-metabolites vs. AA-metabolites were increased, indicating a pro-resolving, anti-inflammatory environment (31) in the PARP-1^{-/-} mice, especially following OXA-sensitization. The formation of the pro-inflammatory COX-metabolites was lower in the skin of the PARP-1^{-/-} mice, which is concordant with a previously determined anti-inflammatory environment (6). PARP-1 has previously been shown to regulate COX-2 expression (32) which may explain the observed decrease in COX-2 metabolites.

It may be suggested that increased FABP7-levels are responsible for the observed alterations of lipid mediator signaling. FABP7 has preference towards n-3, as compared with n-6, PUFAs (33), this may be a plausible explanation for the accumulation of EPA-derived metabolites, and increased ratios of PUFA-metabolites (DHA/AA MET, EPA/AA MET) in the PARP-1^{+/+} mice.

The results of the present study widen the spectrum of altered lipid metabolism upon PARP-1 expression ablation (34,35), by implicating skin eicosanoid and docosanoid

metabolism and signaling. A reduction in PARP-1 expression results in a reduced pro-inflammatory and increased pro-resolving or anti-inflammatory environment in the skin. Higher levels of the DHA and EPA metabolites, and reduced COX-pathway metabolites were previously implicated in a reduction of DNFB-induced CHS (36), peritonitis (31), atopy (37) or allergy (38).

These data are concordant with our previous findings, which showed that genetic or pharmacological inhibition of PARP-1 is capable of protecting against CHS (7,26,39). Notably, differences in eicosanoid and docosanoid metabolism and signaling are also present in unchallenged mice and it may be speculated that these minor changes may render PARP-1^{-/-} mice less susceptible to CHS. Furthermore, the changes to gene expression levels and lipid mediator composition are associated with inflammatory pathologies that are mediated not only by T-helper (Th) 1 or Th2 cells, but also the newly defined Th17 cells, which have previously been associated with the induction of FABPs in psoriasis (40). In conclusion, alteration in skin eicosanoid and docosanoid metabolism and signaling may modify the barrier function of the skin, wherein the role of PARPs remains relatively unexplored.

Acknowledgements

The present study was supported by grants from the National Innovation Office (Baross program Seahorse grant; no. TAMOP-4.2.2. A-11/1/KONV-2012-0025), OTKA (nos. PD83473, K105872, K108308, CNK80709, K104720 and K108308), and the Medical and Health Science Center (Mecenatura no. Mec-8/2011). PB and MS are recipients of the Bolyai fellowship from the Hungarian Academy of Sciences. The authors of the present study would like to acknowledge the technical assistance of Mrs Erzsébet Herbály.

References

- Amé JC, Spenlehauer C and de Murcia G: The PARP superfamily. *Bioessays* 26: 882-893, 2004.
- Szántó M, Brunyánszki A, Kiss B, *et al.*: Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. *Cell Mol Life Sci* 69: 4079-4092, 2012.
- Mehrotra P, Hollenbeck A, Riley JP, *et al.*: Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease. *J Allergy Clin Immunol* 131: 521-531, 2013.
- Mehrotra P, Riley JP, Patel R, *et al.*: PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. *J Biol Chem* 286: 1767-1776, 2011.
- Levaot N, Voytyuk O, Dimitriou I, *et al.*: Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. *Cell* 147: 1324-1339, 2011.
- Bai P and Virág L: Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. *FEBS Lett* 586: 3771-3777, 2012.
- Brunyánszki A, Hegedus C, Szántó M, *et al.*: Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress. *J Invest Dermatol* 130: 2629-2637, 2010.
- Virág L, Szabó E, Bakondi E, *et al.*: Nitric oxide-peroxynitrite-poly (ADP-ribose) polymerase pathway in the skin. *Exp Dermatol* 11: 189-202, 2002.
- Bakondi E, Gönczi M, Szabó E, *et al.*: Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes. *J Invest Dermatol* 121: 88-95, 2003.

10. Selle A, Ullrich O, Harnacke K and Hass R: Retrodifferentiation and rejuvenation of senescent monocytic cells requires PARP-1. *Exp Gerontol* 42: 554-562, 2007.
11. Aldinucci A, Gerlini G, Fossati S, *et al*: A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. *J Immunol* 179: 305-312, 2007.
12. Mocchegiani E, Muzzioli M, Giacconi R, *et al*: Metallothioneins/PARP-1/IL-6 interplay on natural killer cell activity in elderly: parallelism with nonagenarians and old infected humans. Effect of zinc supply. *Mech Ageing Dev* 124: 459-468, 2003.
13. Zerfaoui M, Errami Y, Naura AS, *et al*: Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. *J Immunol* 185: 1894-1902, 2010.
14. Rolli J, Rosenblatt-Velin N, Li J, *et al*: Bacterial flagellin triggers cardiac innate immune responses and acute contractile dysfunction. *PLoS One* 5: e12687, 2010.
15. Eaves-Pyles T, Murthy K, Liaudet L, *et al*: Flagellin, a novel mediator of *Salmonella*-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. *J Immunol* 166: 1248-1260, 2001.
16. Liaudet L, Deb A, Pacher P, *et al*: The Flagellin-TLR5 axis: Therapeutic opportunities. *Drug News Perspect* 15: 397-409, 2002.
17. Liaudet L, Murthy KG, Mabley JG, *et al*: Comparison of inflammation, organ damage, and oxidant stress induced by *Salmonella enterica* serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide. *Infect Immun* 70: 192-198, 2002.
18. Liaudet L, Szabó C, Evgenov OV, *et al*: Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. *Shock* 19: 131-137, 2003.
19. Murthy KG, Deb A, Goonesekera S, Szabó C and Salzman AL: Identification of conserved domains in *Salmonella muenchen* flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. *J Biol Chem* 279: 5667-5675, 2004.
20. Pacher P, Beckman JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 87: 315-424, 2007.
21. Grabbe S and Schwarz T: Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. *Immunol Today* 19: 37-44, 1998.
22. Grabbe S, Steinert M, Mahnke K, *et al*: Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. *J Clin Invest* 98: 1158-1164, 1996.
23. Olmos A, Giner RM, Recio MC, *et al*: Effects of plant alkylphenols on cytokine production, tyrosine nitration and inflammatory damage in the efferent phase of contact hypersensitivity. *Br J Pharmacol* 152: 366-373, 2007.
24. Haskó G, Mabley JG, Németh ZH, *et al*: Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. *Mol Med* 8: 283-289, 2002.
25. Soriano F, Virág L, Jagtap P, *et al*: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. *Nat Med* 7: 108-113, 2001.
26. Bai P, Hegedus C, Szabó E, *et al*: Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity. *J Invest Dermatol* 129: 234-238, 2009.
27. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P, de Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc Natl Acad Sci USA* 94: 7303-7307, 1997.
28. Szklenar M, Kalkowski J, Stangl V, Lorenz M and Rühl R: Eicosanoids and docosanoids in plasma and aorta of healthy and atherosclerotic rabbits. *J Vasc Res* 50: 372-382, 2013.
29. Rühl R: Method to determine 4-oxo-retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/diode-array detection atmospheric pressure chemical ionisation tandem mass spectrometry. *Rapid Commun Mass Spectrom* 20: 2497-2504, 2006.
30. Szabó E, Virág L, Bakondi E, *et al*: Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. *J Invest Dermatol* 117: 74-80, 2001.
31. Elabdeen HR, Mustafa M, Szklenar M, *et al*: Ratio of pro-resolving and pro-inflammatory lipid mediator precursors as potential markers for aggressive periodontitis. *PLoS One* 8: e70838, 2013.
32. Lin Y, Tang X, Zhu Y, Shu T and Han X: Identification of PARP-1 as one of the transcription factors binding to the repressor element in the promoter region of COX-2. *Arch Biochem Biophys* 505: 123-129, 2011.
33. Hanhoff T, Lücke C and Spener F: Insights into binding of fatty acids by fatty acid binding proteins. *Mol Cell Biochem* 239: 45-54, 2002.
34. Bai P and Cantó C: The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. *Cell Metab* 16: 290-295, 2012.
35. Szántó M, Brunyánszki A, Márton J, *et al*: Deletion of PARP-2 induces hepatic cholesterol accumulation and decrease in HDL levels. *Biochem Biophys Acta* 1842: 594-602, 2014.
36. Tomobe YI, Morizawa K, Tsuchida M, *et al*: Dietary docosahexaenoic acid suppresses inflammation and immunoresponses in contact hypersensitivity reaction in mice. *Lipids* 35: 61-69, 2000.
37. Abba C, Mussa PP, Vercelli A and Raviri G: Essential fatty acids supplementation in different-stage atopic dogs fed on a controlled diet. *J Anim Physiol Anim Nutr (Berl)* 89: 203-207, 2005.
38. Rühl R, Koch C, Marosvölgyi T, *et al*: Fatty acid composition of serum lipid classes in mice following allergic sensitisation with or without dietary docosahexaenoic acid-enriched fish oil substitution. *Br J Nutr* 99: 1239-1246, 2008.
39. Virág L and Szabó C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. *Pharmacol Rev* 54: 375-429, 2002.
40. Madsen P, Rasmussen HH, Leffers H, Honoré B and Celis JE: Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. *J Invest Dermatol* 99: 299-305, 1992.